Literature DB >> 16508716

Hypopituitarism as a consequence of brain tumours and radiotherapy.

Ken H Darzy1, Stephen M Shalet.   

Abstract

Radiation-induced damage to the hypothalamic-pituitary (h-p) axis is associated with a wide spectrum of subtle and frank abnormalities in anterior pituitary hormones secretion. The frequency, rapidity of onset and the severity of these abnormalities correlate with the total radiation dose delivered to the h-p axis, as well as the fraction size, younger age at irradiation, prior pituitary compromise by tumour and/or surgery and the length of follow up. Whilst, the hypothalamus is the primary site of radiation-induced damage, secondary pituitary atrophy evolves with time due to impaired secretion of hypothalamic trophic factors and/or time-dependent direct radiation-induced damage. Selective radiosensitivity in the neuroendocrine axes with the GH axis being the most vulnerable to radiation damage accounts for the high frequency of GH deficiency, which usually occurs in isolation following irradiation of the h-p axis with doses less than 30 Gy. With higher radiation doses (30-50 Gy), however, the frequency of GH insufficiency substantially increases and can be as high as 50-100%, and TSH and ACTH deficiency start to occur with a long-term cumulative frequency of 3-6%. Abnormalities in gonadotrophin secretion are dose-dependent; precocious puberty can occur after radiation dose less than 30 Gy in girls only, and in both sexes equally with a radiation dose of 30-50 Gy. Gonadotrophin deficiency occurs infrequently and is usually a long-term complication following a minimum radiation dose of 30 Gy. Hyperprolactinemia, due to hypothalamic damage leading to reduced dopamine release, has been described in both sexes and all ages but is mostly seen in young women after intensive irradiation and is usually subclinical. A much higher incidence of gonadotrophin, ACTH and TSH deficiencies (30-60% after 10 years) occur after more intensive irradiation (>70 Gy) used for nasopharyngeal carcinomas and tumours of the skull base and following conventional irradiation (30-50 Gy) for pituitary tumours. Radiation-induced anterior pituitary hormone deficiencies are irreversible and progressive. Regular testing is mandatory to ensure timely diagnosis and early hormone replacement therapy to improve linear growth and prevent short stature in children cured from cancer, and in adults preserve sexual function, prevent ill health and osteoporosis and improve the quality of life.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16508716     DOI: 10.1007/s11102-006-6042-4

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  83 in total

1.  Growth failure in children after total body irradiation preparative for bone marrow transplantation.

Authors:  L Hovi; U M Saarinen; M A Siimes
Journal:  Bone Marrow Transplant       Date:  1991       Impact factor: 5.483

2.  Growth hormone release in children after cranial irradiation.

Authors:  B Lannering; K Albertsson-Wikland
Journal:  Horm Res       Date:  1987

3.  Restoration of normal pituitary gonadotropin reserve by administration of luteinizing-hormone-releasing hormone in patients with hypogonadotropic hypogonadism.

Authors:  Y Yoshimoto; K Moridera; H Imura
Journal:  N Engl J Med       Date:  1975-01-30       Impact factor: 91.245

4.  A novel variant of growth hormone (GH) insufficiency following low dose cranial irradiation.

Authors:  E C Crowne; C Moore; W H Wallace; A L Ogilvy-Stuart; G M Addison; P H Morris-Jones; S M Shalet
Journal:  Clin Endocrinol (Oxf)       Date:  1992-01       Impact factor: 3.478

5.  Thyroid function in survivors of childhood acute lymphoblastic leukaemia: the significance of prophylactic cranial irradiation.

Authors:  A Lando; K Holm; K Nysom; U Feldt-Rasmussen; J H Petersen; J Müller
Journal:  Clin Endocrinol (Oxf)       Date:  2001-07       Impact factor: 3.478

6.  Cranial irradiation for cerebral and nasopharyngeal tumours in children: evidence for the production of a hypothalamic defect in growth hormone release.

Authors:  A Blacklay; A Grossman; R J Ross; M O Savage; P S Davies; P N Plowman; D H Coy; G M Besser
Journal:  J Endocrinol       Date:  1986-01       Impact factor: 4.286

7.  Growth hormone function and treatment following bone marrow transplant for neuroblastoma.

Authors:  J S Olshan; S M Willi; D Gruccio; T Moshang
Journal:  Bone Marrow Transplant       Date:  1993-10       Impact factor: 5.483

8.  Precocious and premature puberty associated with treatment of acute lymphoblastic leukaemia.

Authors:  A D Leiper; R Stanhope; P Kitching; J M Chessells
Journal:  Arch Dis Child       Date:  1987-11       Impact factor: 3.791

9.  Hypothalamic, pituitary and thyroid dysfunction after radiotherapy to the head and neck.

Authors:  N A Samaan; R Vieto; P N Schultz; M Maor; R T Meoz; V A Sampiere; A Cangir; H L Ried; R H Jesse
Journal:  Int J Radiat Oncol Biol Phys       Date:  1982-11       Impact factor: 7.038

10.  A longitudinal study on growth and spontaneous growth hormone (GH) secretion in children with irradiated brain tumors.

Authors:  K Albertsson-Wikland; B Lannering; I Márky; L Mellander; U Wannholt
Journal:  Acta Paediatr Scand       Date:  1987-11
View more
  25 in total

1.  Empty sella/pituitary atrophy and endocrine impairments as a consequence of radiation and chemotherapy in long-term survivors of childhood leukemia.

Authors:  Yoshikazu Nishi; Kazuko Hamamoto; Naoto Fujita; Satoshi Okada
Journal:  Int J Hematol       Date:  2011-09-29       Impact factor: 2.490

Review 2.  Screening and management of adverse endocrine outcomes in adult survivors of childhood and adolescent cancer.

Authors:  Emily S Tonorezos; Melissa M Hudson; Angela B Edgar; Leontien C Kremer; Charles A Sklar; W Hamish B Wallace; Kevin C Oeffinger
Journal:  Lancet Diabetes Endocrinol       Date:  2015-04-12       Impact factor: 32.069

Review 3.  Pediatric brain tumor treatment: growth consequences and their management.

Authors:  Sogol Mostoufi-Moab; Adda Grimberg
Journal:  Pediatr Endocrinol Rev       Date:  2010-09

Review 4.  Chronic disease in the Childhood Cancer Survivor Study cohort: a review of published findings.

Authors:  Lisa Diller; Eric J Chow; James G Gurney; Melissa M Hudson; Nina S Kadin-Lottick; Toana I Kawashima; Wendy M Leisenring; Lillian R Meacham; Ann C Mertens; Daniel A Mulrooney; Kevin C Oeffinger; Roger J Packer; Leslie L Robison; Charles A Sklar
Journal:  J Clin Oncol       Date:  2009-04-13       Impact factor: 44.544

Review 5.  Optimal management of non-functioning pituitary adenomas.

Authors:  Yona Greenman; Naftali Stern
Journal:  Endocrine       Date:  2015-07-16       Impact factor: 3.633

Review 6.  The Treatment of Cushing's Disease.

Authors:  Rosario Pivonello; Monica De Leo; Alessia Cozzolino; Annamaria Colao
Journal:  Endocr Rev       Date:  2015-06-11       Impact factor: 19.871

7.  Pituitary hormone dysfunction after proton beam radiation therapy in children with brain tumors.

Authors:  Vidhya Viswanathan; Kamnesh R Pradhan; Erica A Eugster
Journal:  Endocr Pract       Date:  2011 Nov-Dec       Impact factor: 3.443

8.  Endocrine and Metabolic Disorders in Survivors of Childhood Cancers and Health-Related Quality of Life and Physical Activity.

Authors:  Kamnesh R Pradhan; Yan Chen; Sogol Moustoufi-Moab; Kevin Krull; Kevin C Oeffinger; Charles Sklar; Gregory T Armstrong; Kirsten K Ness; Leslie Robison; Yutaka Yasui; Paul C Nathan
Journal:  J Clin Endocrinol Metab       Date:  2019-11-01       Impact factor: 5.958

9.  Pilot study on sex hormone levels and fertility in women with malignant gliomas.

Authors:  Matthias Preusser; Stefanie Seywald; Katarzyna Elandt; Christine Kurz; Andrea Rottenfusser; Karin Dieckmann; Gabriele Altorjai; Christoph C Zielinski; Christine Marosi
Journal:  J Neurooncol       Date:  2011-11-20       Impact factor: 4.130

Review 10.  Caring for adult survivors of childhood cancer.

Authors:  Daniel A Mulrooney; Joseph P Neglia; Melissa M Hudson
Journal:  Curr Treat Options Oncol       Date:  2008-03-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.